Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Background: Erlotinib-based combination therapy leads to increased efficacy but also toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment tolerability, but few evidences are available regarding its efficacy at reduced dose. This randomized phase-2 study intends to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shen, Zhang, Zhen, Fang, Wenfeng, Zhang, Yaxiong, Zhang, Zhonghan, Hong, Shaodong, Ma, Yuxiang, Zhou, Ting, Yang, Yunpeng, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683781/
https://www.ncbi.nlm.nih.gov/pubmed/33244458
http://dx.doi.org/10.3389/fonc.2020.587849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683781/
https://www.ncbi.nlm.nih.gov/pubmed/33244458
http://dx.doi.org/10.3389/fonc.2020.587849

Ejemplares similares